Spectrum Of Activity
Community-acquired pneumoniaAcute exacerbation of chronic bronchitis (AECB)Acute bacterial sinusitisUncomplicated SSTIComplicated SSTIComplicated intraabdominal infection400 mg PO q24h x7-14d400 mg PO/IV q24h x5d400 mg PO/IV q24h x10d400 mg PO/IV q24h x7d400 mg PO/IV q24h x7-21d400 mg PO/IV q24h x5-14dMay switch from IV to oral administration without dose adjustmentNo renal dose adjustment
Safety and efficacy in pediatric patients <18y of age have not been established
No dose adjustment
Pneumonia including CAP, HAP, aspiration
Some intra-abdominal infections
Black Box Warning:
Discontinue moxifloxacin and avoid use of fluoroquinolones in patients with these serious adverse reactions.
Reserve use of moxifloxacin for patients with no alternative treatment options for acute bacterial sinusitis or acute bacterial exacerbation of chronic bronchitis.
Avoid in patients with known history of myasthenia gravis.
Monitor QTc in patients with increased risk.
Monitor creatinine BUN in patients with impaired renal function.
Monitor serum magnesium levels, hematopoietic, renal and hepatic functions.
Perform serologic syphillis testing upon diagnosis of gonorrhea with follow-up testing 3 months after initiation.
Perform ophthalmologic evaluations in patients reporting visual disturbances.
Clostirdioides difficile overgrowth patients with diarrhea.
Tendinopathy and rupture
Weakness exacerbation in myasthenia gravis
CNS toxicity including confusion, psychosis
QTc prolongation - increased risk with other agents that prolong QTc
Divalent cations including Ca, Mg - decreased absorption
Warfarin - increased INR
Rifampin - decrease moxifloxacin levels
Antimicrobial class: Fluoroquinolone
Pregnancy category: C
Average serum half life: 10-14 hours
Biliary penetration: Therapeutic
CSF penetration: Therapeutic
Lung penetration: Therapeutic
Urine penetration: Poor